Loading
BostonGene's tumour test that adds a reading of the immune cells around the cancer to the usual list of gene changes.
The Tumor Portrait test from BostonGene identifies biomarkers for response to therapy in advanced solid tumours by combining comprehensive genomic profiling with an analysis of the tumour microenvironment, covering more than 19,000 genes. BostonGene publishes cancer-specific biomarker lists for breast, colorectal, gastric, pancreatic, urinary tract, kidney, prostate, non-small cell lung, head and neck, ovarian, melanoma and sarcoma, and for follicular and diffuse large B-cell lymphoma. Immunohistochemistry for PD-L1 and mismatch repair can be added. The microenvironment types come from BostonGene's transcriptomic classification of more than 10,000 patients into four subtypes conserved across 20 cancers, published in Cancer Cell in 2021. All analyses are run in BostonGene's CAP-accredited, CLIA-certified laboratory.
Exome and transcriptome sequencing of the tumour, covering more than 19,000 genes, combined with a classification of the tumour microenvironment from the RNA data.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tumor Portrait" OR ABSTRACT:"Tumor Portrait" OR TITLE:"BostonGene Tumor Portrait" OR ABSTRACT:"BostonGene Tumor Portrait" OR TITLE:"Tumor Portrait test" OR ABSTRACT:"Tumor Portrait test") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tumor Portrait, not a curated reading list.
Shares Immunotherapy response and its prediction, TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Next-generation sequencing (NGS), RNA sequencing & expression profiling and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/